#United States #New York #Levi and Korsinsky #Securities Class Action #Tenax Therapeutics

Tenax Therapeutics Lawsuit: Important Update for Shareholders

In recent developments, the law firm Levi & Korsinsky, LLP has issued a reminder for shareholders of Tenax Therapeutics, Inc. about the urgent deadline approaching on December 28, 2026. This date marks the end of the period for investors to apply for lead plaintiff status in a securities class action lawsuit involving shares bought between November 13, 2023, and August 7, 2026. This class action is crucial for those who have suffered financial losses in Tenax's recent share price decline.

Background of the Case

Tenax Therapeutics (NASDAQ: TENX) has been embroiled in a lawsuit that accuses the company of misleading investors regarding the efficacy of its product, TNX-103. Following the FDA’s approval of the Investigational New Drug application in late 2023, Tenax experienced a strong initial trajectory. However, the fiasco culminated in a staggering 89.77% drop in share value on August 10, 2026, after the company announced that TNX-103 did not meet its primary endpoint in a critical Phase 3 clinical trial.

Investor Participation and Options

The lead plaintiff in this type of securities class action is typically a shareholder who has incurred significant losses and is expected to provide oversight throughout the legal process. Interested investors are encouraged to contact attorney Joseph E. Levi at Levi & Korsinsky to determine their eligibility to become the lead plaintiff or to learn about their legal options if they have already sold their shares.

Key Timeline of Events

• - November 13, 2023: The class action period begins with the announcement of FDA clearance for TNX-103.
• - August 10, 2026: Tenax experiences catastrophic share price drop following disappointing trial results.
• - December 28, 2026: Deadline for potential lead plaintiffs to step forward.

According to the allegations in the lawsuit, Tenax made exaggerated claims about TNX-103's clinical and regulatory success, leading investors to buy shares under false pretenses. This misrepresentation raises significant questions regarding the accountability of the company’s management and its fiduciary responsibilities to ensure accurate and timely disclosures to the public and its investors.

Legislative Framework and Legal Considerations

The lawsuit has been filed in the United States District Court for the Middle District of North Carolina, under the Private Securities Litigation Reform Act of 1995, which facilitates protections for investors in cases of securities fraud. Investors can still recover losses even if they have sold their TENX shares, as eligibility depends on when the shares were purchased, not on current holdings.

Frequently Asked Questions

1. What allegations are present in the TENX lawsuit?
Plaintiffs allege that Tenax made materially false statements regarding TNX-103's effectiveness and its commercial viability, which misled investors.
2. What if Tenax goes bankrupt during the lawsuit?
Securities class action claims can often survive bankruptcy, opening avenues for potential recovery through available settlement funds.
3. What does it cost to participate in this lawsuit?
Participation can be free initially, as there are no upfront fees for legal representation in class action suits; fees are typically contingent upon successful recovery.

Conclusion

With the deadline for investors approaching, it’s crucial for shareholders of Tenax Therapeutics to understand their rights and options. By staying informed and proactive, investors can navigate the complexities of this securities class action and potentially recover their losses.

For additional information and assistance, reach out to Levi & Korsinsky, LLP at (212) 363-7500 or visit their website. It’s imperative to act swiftly as the December 28 deadline looms large on the horizon.